Genetic testing startup 23andMe, which filed for bankruptcy earlier this year, announced on Monday that it has agreed to sell the genetic data of its 15 million users, along with its core business, to drug developer Regeneron Pharmaceuticals. Regeneron told 23andMe customers that it would adhere to 23andMe's privacy policy, which allows customers to request to delete their personal information. Baras explained that the Regeneron Genetics Center has experience with genetic data, processing the genetic information of nearly three million people in research studies since it was founded in 2013. Regeneron "shares 23andMe's founding vision of the power of genetics and data," Baras stated. Under the acquisition, 23andMe will continue its daily operations as a personal genomics service, but as a subsidiary of Regeneron, and continue to offer genetic testing.